Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system.
Costacurta F, Dodaro A, Bante D, Schöppe H, Sprenger B, Moghadasi SA, Fleischmann J, Pavan M, Bassani D, Menin S, Rauch S, Krismer L, Sauerwein A, Heberle A, Rabensteiner T, Ho J, Harris RS, Stefan E, Schneider R, Kaserer T, Moro S, von Laer D, Heilmann E. Costacurta F, et al. Among authors: moghadasi sa. bioRxiv [Preprint]. 2023 Oct 4:2023.09.22.558628. doi: 10.1101/2023.09.22.558628. bioRxiv. 2023. Update in: PLoS Pathog. 2024 Sep 11;20(9):e1012522. doi: 10.1371/journal.ppat.1012522 PMID: 37808638 Free PMC article. Updated. Preprint.
Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 Mpro/3CLpro in Living Cells.
Moghadasi SA, Esler MA, Otsuka Y, Becker JT, Moraes SN, Anderson CB, Chamakuri S, Belica C, Wick C, Harki DA, Young DW, Scampavia L, Spicer TP, Shi K, Aihara H, Brown WL, Harris RS. Moghadasi SA, et al. mBio. 2022 Jun 28;13(3):e0078422. doi: 10.1128/mbio.00784-22. Epub 2022 Apr 26. mBio. 2022. PMID: 35471084 Free PMC article.
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors.
Moghadasi SA, Heilmann E, Khalil AM, Nnabuife C, Kearns FL, Ye C, Moraes SN, Costacurta F, Esler MA, Aihara H, von Laer D, Martinez-Sobrido L, Palzkill T, Amaro RE, Harris RS. Moghadasi SA, et al. bioRxiv [Preprint]. 2022 Dec 26:2022.08.07.503099. doi: 10.1101/2022.08.07.503099. bioRxiv. 2022. Update in: Sci Adv. 2023 Mar 29;9(13):eade8778. doi: 10.1126/sciadv.ade8778 PMID: 35982678 Free PMC article. Updated. Preprint.
SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376.
Heilmann E, Costacurta F, Moghadasi SA, Ye C, Pavan M, Bassani D, Volland A, Ascher C, Weiss AKH, Bante D, Harris RS, Moro S, Rupp B, Martinez-Sobrido L, von Laer D. Heilmann E, et al. Among authors: moghadasi sa. Sci Transl Med. 2023 Jan 11;15(678):eabq7360. doi: 10.1126/scitranslmed.abq7360. Epub 2023 Jan 11. Sci Transl Med. 2023. PMID: 36194133 Free PMC article.
Rapid resistance profiling of SARS-CoV-2 protease inhibitors.
Moghadasi SA, Biswas RG, Harki DA, Harris RS. Moghadasi SA, et al. bioRxiv [Preprint]. 2023 Feb 27:2023.02.25.530000. doi: 10.1101/2023.02.25.530000. bioRxiv. 2023. PMID: 36909573 Free PMC article. Updated. Preprint.
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors.
Moghadasi SA, Heilmann E, Khalil AM, Nnabuife C, Kearns FL, Ye C, Moraes SN, Costacurta F, Esler MA, Aihara H, von Laer D, Martinez-Sobrido L, Palzkill T, Amaro RE, Harris RS. Moghadasi SA, et al. Sci Adv. 2023 Mar 29;9(13):eade8778. doi: 10.1126/sciadv.ade8778. Epub 2023 Mar 29. Sci Adv. 2023. PMID: 36989354 Free PMC article.
20 results